← Today’s ReceiptsSource pending
Public-record receiptR-FLSource pending
Ashley Moody disclosed BUY $LLY
Here’s the public record: who traded, what they disclosed, when it happened, how late it appeared, and what context is attached.
Trade range
$100K – $250K
Filed
2025-03-23
Trade date
2025-03-06
Disclosure lag
17 days after trade
Why this receipt matters
A quick read before you share it.
These are factual context points from the receipt and linked public-record data. They explain why the disclosure may be worth opening, not whether anyone acted improperly.
1The disclosure is tracked with source status pending, so treat it as a record to verify rather than a finished source trail.
2The filing appeared 17 days after trade, which helps separate trade timing from filing timing.
3The disclosed range is $100K – $250K, which is the public reporting band rather than an exact profit or loss figure.
46 nearby same-ticker disclosures appeared in the surrounding 30-day window.
5Committee context is available for Ashley Moody, but PoliWealth treats it as context - not proof of intent or wrongdoing.
6Related public-record context includes 17 lobbying filings.
Source
source pending
Source: indexed congressional disclosure; official source link pending · filed 2025-03-23 · disclosed 17d after transaction
Market context
Eli Lilly and Company
Sector: Healthcare
Factual flags
- 17 lobbying filings linked to this ticker.
- 6 nearby same-ticker disclosures in the surrounding 30-day window.
- Traded LLY 27d after lobbying filing by ELI LILLY AND COMPANY ($1,900,000) (committee overlap: Healthcare)
- 10 trades filed on 2025-03-23 (batch dump)
- 3 members traded LLY within 7 days (starting 2025-03-03)
- Sits on committee with jurisdiction over healthcare/pharma/biotech sector — traded LLY on 2025-03-06
- Trade upper bound: $250,000
Member trail
Ashley Moody
U.S. Senate · FL
Senate Committee on Armed ServicesSenate Committee on HealthEducationLaborand PensionsSenate Committee on Homeland Security and Governmental Affairs
Ticker trail
$LLY
Eli Lilly and Company
Follow this tickerAlert me when this ticker gets a new congressional receipt. This page reports public disclosures and factual context only. It does not determine intent, is not an accusation, and is not investment advice.